10-K: ENDRA Life Sciences Faces Going Concern, Delays FDA Submission

ENDRA Life Sciences reported a net loss of $7.03 million for 2025, faces substantial doubt about its ability to continue as a going concern, and is evaluating strategic alternatives while delaying its key FDA submission.

Summary

• Reported a net loss of $7,027,410 for the fiscal year ended December 31, 2025, an improvement from $11,507,947 in 2024.
• Accumulated deficit increased to $110,465,509 as of December 31, 2025.
• Cash balance significantly decreased to $762,365 as of December 31, 2025, from $3,229,480 in 2024.
• Auditors have raised substantial doubt about the company's ability to continue as a going concern.
• Implemented cost reduction measures in 2026, including a reduction in headcount and prioritizing development over clinical activities, impacting the timing of a future FDA De Novo submission for its TAEUS liver application.
• The Board of Directors initiated a process on March 25, 2026, to evaluate a range of strategic alternatives, including investments, mergers, asset sales, or a sale of the company.
• Expanded business strategy in 2025 to include a Digital Asset Treasury (DAT) initiative, managed with Arca Investment Management, focusing on decentralized finance (DeFi) assets like HYPE.
• Purchased $3,000,000 of digital intangible assets (HYPE tokens) in 2025, which had a fair value of $2,009,960 and an unrealized loss of $995,161 as of December 31, 2025.
• Recognized $5,121 in digital asset staking compensation for the year ended December 31, 2025.
• Research and development expenses decreased by 42% to $1,849,996 in 2025 from $3,190,293 in 2024.
• Sales and marketing expenses decreased by 67% to $189,470 in 2025 from $571,040 in 2024.
• General and administrative expenses decreased by 47% to $3,723,635 in 2025 from $7,055,814 in 2024, primarily due to a $2,525,179 inventory reserve in 2024 that was not present in 2025.
• The company is not in compliance with Nasdaq's minimum stockholders' equity requirement and expects a delisting determination letter, planning to request a hearing.
• As of March 31, 2026, there were 1,240,751 shares of common stock outstanding.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing with very low sentiment due to the explicit 'going concern' warning, significant cash burn, delays in critical regulatory approvals, and the high-risk nature of the new digital asset treasury strategy, all of which point to severe operational and financial challenges.

Positives

• Net loss decreased by 38.8% to $7.03 million in 2025 from $11.51 million in 2024.
• Cost reduction measures, including headcount reduction and prioritization of development, are expected to extend the operating runway.
• The company has a patent portfolio consisting of 42 issued U.S. patents and 45 issued foreign patents, along with pending applications, protecting its TAEUS technology.
• Successfully obtained CE mark approval for its TAEUS FLIP (Fatty Liver Imaging Probe) System in Europe in March 2020.
• The Digital Asset Treasury (DAT) initiative aims to optimize capital preservation and generate non-dilutive returns, with $5,121 in staking compensation recognized in 2025.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
• Cash balance significantly declined to $762,365 at year-end 2025 from $3,229,480 in 2024.
• Accumulated deficit increased to $110.47 million as of December 31, 2025.
• Delay in the timing of a future De Novo submission to the FDA for the TAEUS liver application due to cost reduction measures and halting clinical activity.
• The original FDA De Novo application was formally closed on April 24, 2024, due to the need for additional clinical and device test data, and cybersecurity responses.
• Not in compliance with Nasdaq's minimum stockholders' equity requirement ($2,500,000) as of December 31, 2025, and expects a delisting determination letter.
• Unrealized loss of $995,161 on digital assets as of December 31, 2025, reflecting the volatility and potential risks of the Digital Asset Treasury strategy.
• Significant reduction in workforce implemented on March 19, 2026, incurring approximately $51,282 in severance payments.
• Limited commercial experience and no revenue generated from TAEUS technology as of December 31, 2025.

Risks

• Limited commercial experience, limited cash, and history of losses.
• Ability to obtain adequate financing to fund business operations and achieve profitability.
• Delays and changes in regulatory requirements, policy, and guidelines, including potential delays in submitting required regulatory applications or other submissions with respect to FDA or other regulatory agency approval.
• Ability to obtain and maintain required CE mark certifications and secure required FDA and other governmental approvals for TAEUS applications.
• Ability to develop commercially feasible applications based on TAEUS technology.
• Market acceptance of TAEUS technology by physicians, patients, and third-party payors.
• Effect of macroeconomic conditions on the business.
• Results of human studies may be negative or inconclusive.
• Ability to find and maintain development partners.
• Reliance on third parties, collaborations, strategic alliances, and licensing arrangements to complete business strategy.
• Amount and nature of competition in the industry, including from larger companies with greater resources.
• Ability to protect intellectual property, which entails significant expense and resources.
• Potential changes in the healthcare industry or third-party reimbursement practices.
• Ability to comply with regulation by various federal, state, local, and foreign governmental agencies and to maintain necessary regulatory clearances or approvals.
• Ability to regain compliance with Nasdaq listing standards, including minimum bid price and stockholders' equity requirements.
• Ability to successfully execute on the new digital asset treasury strategy.
• Risks related to regulatory developments regarding digital assets and digital asset markets, which could adversely affect business, financial condition, and results of operations.
• Volatile and unpredictable cycles in the digital asset industry.
• Uncertainty in the accounting treatment of digital assets.
• Dependence on senior management team.
• Product misuse and potential adverse treatment outcomes if products are used by non-licensed or untrained practitioners.
• Inadequate level of reimbursement by governmental programs and other third-party payors for planned products or associated procedures.
• Limited data regarding the efficacy of TAEUS platform applications.
• Inability to successfully commercialize applications if they do not perform in accordance with expectations.
• Inability to realize benefits from strategic alliances, collaborations, or licensing arrangements.
• Dependence on third parties to design and manufacture, and seek regulatory approval of, TAEUS applications.
• Problems in developing internal and third-party marketing and distribution capabilities.
• Inability to manage business growth effectively.
• Misdiagnosis, warranty, and other claims, as well as product field actions and regulatory proceedings.
• Public health crises (e.g., pandemics) could adversely impact business, including pre-sales activities, clinical trials, and regulatory approvals.
• Policing unauthorized use of proprietary rights can be difficult, expensive, and time-consuming.
• Intellectual property rights may not provide adequate protection, permitting third parties to compete more effectively.
• Failure to comply with laws and regulations could harm the business.
• Disruptions at the FDA, including due to workforce reductions or inadequate funding, could prevent normal functions.
• Healthcare reform measures could hinder or prevent commercial success.
• Compliance with environmental laws and regulations could be expensive.
• Stock price volatility due to factors unrelated to operating performance or prospects, including potential short squeezes.
• Securities litigation, which is expensive and could divert management attention.
• Inability to implement and maintain effective internal control over financial reporting, including remediating current material weaknesses.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Future sales and issuances of common stock or rights to purchase common stock could result in dilution.
• Charter documents and Delaware law may inhibit a takeover.
• Emergence or growth of other digital assets could negatively impact the price of cryptocurrencies held.
• Accounting treatment of cryptocurrency holdings could increase volatility of results.
• Digital asset holdings are generally less liquid than cash and cash equivalents.
• Active management of digital assets (staking, options overlays, DeFi protocols) involves technical risks (smart contract vulnerabilities, slashing penalties, exchange failures).
• Loss of private keys, security breaches, or insolvency of a custodian could result in total loss of digital asset holdings.
• Digital asset markets are subject to evolving and potentially unfavorable regulatory developments.
• Classification as an investment company under the Investment Company Act if digital asset holdings are determined to be investment securities.
• Uncertain U.S. and foreign tax treatment of digital assets could result in unexpected tax liabilities.
• Common stock price may become highly correlated to the market price of digital assets, leading to extreme volatility.
• Possibility that certain cryptocurrencies may be classified as securities, subjecting the company to additional regulation.
• Not subject to legal and regulatory obligations that apply to investment companies or investment advisers.
• Unfavorable national or global economic conditions or political developments could adversely affect business.
• Cash and cash equivalents could be adversely affected if financial institutions fail.
• Business and operations are subject to risks related to climate change and natural disasters.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances the engineering design and development of its TAEUS technology, acquires inventory, completes regulatory filings (including clinical studies for the planned FDA De Novo application), hires sales and marketing teams, and develops other applications. Future funding requirements are dependent on many factors, including regulatory outcomes, clinical study progress, and commercialization success. The company will need to raise additional capital to fund operations through 2026 and beyond, and its ability to do so is uncertain.

Management Comments

• "We continue to examine the positioning (need, cost, and technical considerations) of our TAEUS platform in the rapidly evolving market for point-of-care assessment of liver fat disease against other opportunities for our platform, such as monitoring of thermo-ablative surgical procedures."
• "In 2026, we implemented cost reduction measures, including a reduction in headcount and prioritization of development activities over clinical ones, to extend our operating runway and focus resources on product improvements and regulatory strategy for our TAEUS liver application."
• "These actions are expected to impact the timing of certain development activities, including delaying the timing of a future De Novo submission to the U.S. Food and Drug Administration (FDA) relating to our TAEUS liver application."
• "We are continuing to refine our clinical and regulatory strategy based on prior FDA feedback and ongoing development efforts."
• "On March 25, 2026, the Company announced that its Board of Directors initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value."
• "Our objective is to develop a scalable biomarker solution for metabolic disease assessment and management through a non-invasive, point-of-care approach."
• "Our business model will primarily be a low barrier-to-entry, multi-year, subscription-based business model with monthly recurring revenue (MRR), while also offering a traditional product sale with annual upgrade and maintenance fees."
• "In 2025, the Company expanded its business strategy to include a Digital Asset Treasury (DAT) initiative, managed in collaboration with Arca Investment Management (Arca), which seeks to optimize capital preservation and generate non-dilutive returns through investments in decentralized finance (DeFi) assets."
• "Management identified the following material weakness as of December 31, 2025: insufficient personnel resources within the accounting function to segregate the duties over financial transaction processing and reporting."

Industry Context

StockSavvy.ai notes that ENDRA Life Sciences operates in the highly competitive medical imaging and diagnostic market, facing established giants like GE Healthcare, Royal Philips, and Siemens Healthineers. The company's focus on non-invasive liver fat assessment addresses a significant unmet need in the rapidly growing metabolic disease (MASLD/MASH) and GLP-1 therapy markets, where current diagnostic methods are either expensive (MRI) or invasive (biopsy). However, its limited commercialization and financial challenges contrast sharply with the robust R&D and market penetration capabilities of its larger competitors. The new Digital Asset Treasury strategy is an unusual move for a medical device company, introducing additional volatility and regulatory uncertainty not typically associated with the sector, potentially diverting focus and resources from its core medical technology mission.

Comparison to Industry Standards

• ENDRA's TAEUS technology aims to provide a non-invasive, cost-effective, point-of-care solution for liver fat assessment, which is a significant improvement over expensive MRI-based techniques (e.g., MR PDFF costing $1,500-$2,500 per patient per exam) and invasive liver biopsies used by competitors like Cook Medical and Sterylab S.r.l.
• The company's strategy to integrate thermo-acoustic technology with conventional ultrasound to streamline workflows and reduce operator variability positions it against traditional ultrasound manufacturers (e.g., Canon Corporation, Fujifilm Corporation) by offering enhanced diagnostic capabilities that conventional ultrasound currently lacks for accurate liver fat quantification.
• In the thermal ablation market, ENDRA's potential temperature monitoring application would compete with established surgical temperature probes from companies like Medtronic plc and St. Jude Medical, Inc., aiming to provide a less invasive or more integrated monitoring solution.
• The company's financial performance, with recurring losses and a going concern warning, is significantly below industry standards for commercially viable medical device companies, which typically demonstrate revenue growth and a clear path to profitability or substantial capital reserves.
• The adoption of a Digital Asset Treasury strategy is highly unconventional for a medical technology company and introduces a new layer of financial risk and volatility not typically seen in the sector, making direct comparisons to industry financial benchmarks challenging and potentially unfavorable.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any pending legal proceedings that are believed to have a material adverse effect on the business or financial conditions.
• May be subject to various claims and legal actions arising in the ordinary course of business from time to time.

Related Party Transactions

• The company uses IS Bookkeeping & Payroll, a division of Impact Solve, LLC (dba Impact Solutions), for human resources and payroll processing services. Richard Jacroux, the CFO, is the founder of Impact Solve, LLC. Payments totaled $31,635 in 2025 and $18,693 in 2024.
• In October 2025, Anthony DiGiandomenico, a director, purchased 70,822 shares of common stock and warrants exercisable for 141,644 shares of common stock in a private placement offering at a combined price of $7.06 per share and two warrants.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from future capital raises and potential delisting from Nasdaq. The 'going concern' warning indicates a high risk of total loss of investment. The volatile digital asset strategy adds further uncertainty.
• **Employees**: Workforce reduction implemented in March 2026, leading to severance payments and potential morale impact. Remaining employees face uncertainty due to financial challenges and strategic review.
• **Customers (Pharmaceutical Companies, CROs, Clinics)**: Potential delays in product availability (TAEUS liver application) due to regulatory setbacks and resource prioritization could impact their ability to utilize the technology for metabolic disease assessment and GLP-1 trials.
• **Suppliers/Creditors**: Increased risk due to the company's 'going concern' status and limited liquidity, potentially affecting payment terms or future business relationships.
• **Regulatory Bodies (FDA, EU Notified Bodies)**: Continued engagement required for regulatory approvals, but delays and changes in strategy may lead to increased scrutiny or prolonged review periods.

Next Steps

• Refine clinical and regulatory strategy for TAEUS liver application based on prior FDA feedback and ongoing development efforts.
• Restart clinical activity necessary to support a new FDA De Novo application for TAEUS liver application, contingent on increased resources.
• Continue to evaluate a range of strategic alternatives, including strategic investments, mergers, business combinations, in-licensing or collaboration arrangements, asset sales, or sale or merger of the company.
• Seek to regain compliance with Nasdaq listing standards, including the minimum stockholders' equity requirement, and prepare for a potential hearing.
• Implement measures to remediate material weaknesses in internal control over financial reporting, such as adding accounting personnel or consultants and developing written policies.
• Monitor ongoing developments in the regulatory environment around cryptocurrencies and potentially modify or expand the Digital Asset Treasury strategy.
• Advance the engineering design and development of TAEUS technology and acquire parts and build finished goods inventory.
• Complete regulatory filings required for marketing approval in the United States, including clinical studies to support the planned De Novo application with the FDA.
• Seek to hire a sales and marketing team to market and sell products upon FDA approval.
• Advance development of other TAEUS applications (thermal ablation monitoring, vascular imaging, tissue perfusion analysis).

Key Dates

Recommendation

The filing presents a dire financial situation, explicitly stating 'substantial doubt' about the company's ability to continue as a going concern. Cash reserves are critically low, and the company is actively seeking additional financing, which, if unsuccessful, could lead to cessation of operations. Key product development and regulatory approvals (FDA De Novo submission) are significantly delayed, pushing back any potential revenue generation. Furthermore, the company is non-compliant with Nasdaq listing standards and faces potential delisting. The new digital asset treasury strategy, while intended to generate non-dilutive returns, has already resulted in a significant unrealized loss and introduces additional, highly volatile risks. Given these severe financial, operational, and regulatory challenges, the stock carries an extremely high risk of further decline and potential total loss of investment.

Keywords

Thermo-Acoustic Enhanced Ultrasound, TAEUS, Liver Fat Assessment, MASLD, MASH, GLP-1, Medical Device, Diagnostic Imaging, Digital Asset Treasury, DeFi, Cryptocurrency, HYPE token, SEC Filing, 10-K, Going Concern, Regulatory Approval, FDA De Novo, Nasdaq Listing, Biotech, Healthcare Technology